<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[이뮨온시아 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=42160></link><description><![CDATA[이뮨온시아 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 30 Apr 2026 15:59:56 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2022/12/12_988187250_20221206105031_3267050828.png]]></url></image><language>ko-KR</language><item><title><![CDATA[ImmuneOncia Announces Positive Phase 1a Results of CD47 Monoclonal Antibody IMC-002 in Solid Tumors at ESMO 2023]]></title><link>https://www.newswire.co.kr/newsRead.php?no=976924</link><description><![CDATA[SEOUL--(Korea Newswire)--ImmuneOncia  (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain on October 23rd, 2023.  The dose-escalation study aimed to assess the safety and tolerability, and to establ...]]></description><pubDate>Tue, 24 Oct 2023 09:00:00 +0900</pubDate></item><item><title><![CDATA[ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor]]></title><link>https://www.newswire.co.kr/newsRead.php?no=957601</link><description><![CDATA[SEONGNAM--(Korea Newswire)--ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022) held in Singapore on December 4th, 2022.  The clinical data demonstrated that 6 out of 10 evaluable patients (60%) achi...]]></description><pubDate>Fri, 09 Dec 2022 14:32:45 +0900</pubDate></item></channel></rss>